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The incidence of human papillomavirus (HPV)‑related oropharyngeal cancer is increasing in some 
regions. Nevertheless, the epidemiology of this disease has not been extensively investigated in 
southern europe. We conducted a retrospective cohort study of patients diagnosed with primary 
oropharyngeal cancer from 1991 to 2016. Cancer tissues underwent histopathological evaluation, 
DNA quality control, HPV‑DNA detection and  p16INK4a immunohistochemistry. Data were collected 
from medical records. Factors associated with HPV positivity and time trends were evaluated with 
multivariable Bayesian models. The adjusted prevalence of HPV‑related cases in 864 patients with a 
valid HPV‑DNA result was 9.7%, with HPV‑DNA/p16INK4a double positivity being considered. HPV‑
related oropharyngeal cancer was likely to occur in non‑smokers and non‑drinkers, to be located in the 
tonsil or diagnosed at advanced stages. Time‑trend analysis showed an increasing risk of HPV‑related 
oropharyngeal cancer in the most recent periods (5‑year period increase of 30%). This increase was 
highest and with a clear increasing trend only in the most recent years (2012–2016). The prevalence of 
HPV‑related oropharyngeal cancer started to sharply increase in the most recent years in our setting, 
open
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as occurred two decades ago in areas where most oropharyngeal cancer cases are currently HPV‑
related. Our results provide a comprehensive assessment of the epidemiological landscape of HPV‑
related oropharyngeal cancer in a region of southern europe.
The epidemiology of oropharyngeal cancer (OPC) has dramatically changed in the last two decades after the 
incursion of human papillomavirus (HPV) in the etiological arena of the  disease1. Currently, 29,000 new HPV-
related OPC cases (representing 30% of the total OPC) are estimated to occur every year  worldwide2, with marked 
differences between geographical regions. HPV-related OPC is increasing in some regions of the world such 
as North  America3 and northern  Europe4–7, where most OPC cases are currently HPV-related. The increasing 
trends are thought to be related to a decrease in smoking and increased numbers of sexual partners and oral sex 
 practices8, 9. The role of HPV in OPC has important clinical implications given the distinct nature and marked 
prognostic differences between HPV-related and non-related  patients8, 9. Nevertheless, the epidemiology of 
the disease in southern Europe, where current estimates of HPV prevalence are low (9–24%)2,10, has not been 
extensively investigated. In Spain, only two studies on HPV involvement in selected OPC cases were  available11,12 
until our group recently reported the results of a multicenter retrospective cohort of 788 patients with primary 
OPC consecutively diagnosed between 1991 and  201313. The study identified double positivity for HPV-DNA/
p16INK4a as the biomarker with strongest diagnostic accuracy and prognostic value for HPV-related OPC patients 
and found an HPV prevalence of 7.4% when considering HPV-DNA/p16INK4a double  positivity13. A recent Ital-
ian study also evaluated the role of HPV in patients with newly diagnosed OPC during the period 2000–2018, 
reporting a prevalence of HPV-driven OPC of 32.3% and a higher prevalence in the most recent  years14.
In this study, we aimed to provide an updated assessment of the time trends of HPV prevalence estimates 
in OPC, as well as to evaluate further its epidemiological features compared with other high-burden regions.
Methods
Study design and population. We designed a retrospective cohort study of all new patients diagnosed 
with primary OPC in four hospitals in Catalonia (Spain) from 1991 to 2013 (Catalan Institute of Oncology-Bell-
vitge Hospital, Hospital del Mar, Hospital Parc Taulí and Hospital de la Santa Creu i Sant Pau). We also included 
all patients diagnosed with primary OPC in the latter setting through 2016.
The procedures followed have been previously  described10. Briefly, cases were identified from medical records/
pathology reports of the centers of origin. We included cases fulfilling the following criteria: diagnosis of primary 
invasive cancer of the oropharynx, any histology, codes from the International Classification of Diseases for 
Oncology version 3: Tonsil-C09, C02.4, Base of tongue-C01 and Others (soft palate-C05.1, uvula-C05.2, val-
lecula, glossoepiglottic fold, lateral and posterior wall of the oropharynx, overlapping lesion of the oropharynx 
and oropharynx unspecified-C10, Waldeyer ring-C14.2); and available access to medical records on demographic, 
toxic habits and clinical and follow-up information. Formalin-fixed paraffin embedded (FFPE) primary tumour 
samples from the diagnosis prior to treatment were retrieved when available.
ffpe block processing and histopathological evaluation. All specimens processing was centralized 
at the Catalan Institute of Oncology (ICO). FFPE blocks were re-embedded whenever necessary. The first and 
last sections were used for histopathological evaluation after hematoxylin and eosin (H&E) staining. Two in-
between sections were used for HPV-DNA testing and genotyping; one additional slide was obtained to assess 
 p16INK4a expression, which was performed at Hospital General de l’Hospitalet (Spain) under the manufacturer’s 
standards (Roche mtm Laboratories AG IHC. Heidelberg, Germany). A strong and diffuse nuclear and cytoplas-
mic staining of > 70% of the cancer tissue was considered  p16INK4a-positive15. Since our previous study showed 
high diagnostic accuracy and prognostic value for double positivity for HPV-DNA/p16INK4a13, which is an easier 
diagnostic algorithm to implement in clinical practice than HPV-mRNA testing, we did not further use HPV-
mRNA positivity for the analyses herein presented. A block was classified as adequate for HPV testing if invasive 
cancer was observed in the two H&E stained sections of the specimen.
Pathology review was based on the WHO pathological criteria for head and neck cancer and was performed 
blind with respect to the original local diagnosis and HPV-DNA/p16INK4a results, following a pre-established 
algorithm for diagnostic consensus involving three pathologists, as reported  elsewhere10.
HPV‑DNA detection and genotyping. We used a PCR with the consensus primers SPF10 PCR and a 
DNA enzyme immunoassay (DEIA) to test for the presence of HPV-DNA10,13. HPV genotyping was performed 
using a reverse hybridization line probe assay (LiPA25_v1) on all samples testing positive for viral DNA, target-
ing 25 HPV types with different oncogenic risk (Laboratory Biomedical Products Rijswijk, The Netherlands). 
DNA quality was evaluated in all HPV-DNA negative samples by testing for the tubulin-β gene. All DEIA and 
LiPA25_v1 assays were performed at the ICO.
Statistical analyses. OPC samples testing negative for both viral and human DNA were excluded from the 
analyses. Descriptive, bivariate and unconditional logistic regression analyses were performed to identify inde-
pendent factors associated with HPV etiological involvement in OPC according to double positivity for HPV-
DNA/p16INK4a and  p16INK4a-positivity only. Crude and adjusted odds ratios and their 95% credibility intervals 
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(CI, the Bayesian version of the frequentist confidence intervals but calculated using the posterior distribution 
of the model’s parameters), were estimated. Moreover, crude and adjusted prevalences were estimated, the latter 
to account for other covariates that may have an effect on the prevalence estimates. Adjusted prevalences were 
calculated with R “prediction” function of “prediction”  package16 based on the adjusted models. Histological 
variables were not included in the multivariable analyses as they were considered to be intermediate variables 
in the carcinogenic process, as previously  described17. Bayesian methodology was chosen in all analyses with 
non-informative prior distribution due to lack of data on the distribution of the  parameters18,19 and, moreover, 
because Bayesian methodology is useful to (1) avoid model fitting problems in parameter estimation due to 
small counts, and (2) produce robust  estimators20.
To more specifically assess time trends in HPV-related OPCs in Spain, a log-binomial regression model was 
defined for double positivity for HPV-DNA/p16INK4a and prevalence risk ratios (RR) were obtained, with their 
95% CI. Patients from 1991 were included in the first 5-year period (1992–1996) in order not to lose sample size. 
Multivariable models were adjusted for confounders: age, 5-year periods, gender, tobacco/alcohol consumption, 
subsite and tumour stage.
All analyses were performed using the “bayesglm” function of the “arm”  package19 in R. All possible interac-
tions between variables were assessed and stratified by anatomical subsite.
ethics approval and consent to participate. This study was performed in accordance with the Declara-
tion of Helsinki. The study had formal approval by the ethics committees of the four participating hospitals (i.e. 
Catalan Institute of Oncology-ICO-Hospital Universitari de Bellvitge, Hospital de la Santa Creu i Sant Pau, Hos-
pital del Mar and Hospital Parc Taulí). Adequate measures to ensure data protection, confidentiality, patients’ 
privacy and anonymization were taken into account in compliance with European and Spanish current laws and 
regulations. Informed consent was not available due to the retrospective design of the study and the large pro-
portion of deceased and untraceable patients. Thus, and in accordance to current regulations, informed consent 
was waved off by the ethics committees for patients diagnosed up to 2013. Informed consent was obtained for 
patients diagnosed in 2014–2017.
Results
Supplementary Fig. 1 describes the workflow of the OPC targeted cases, samples collected, processed, tested and 
finally included in the statistical analyses. A total of 76 OPC patients diagnosed in Hospital de la Santa Creu i 
Sant Pau between 2013 and 2016 were added to the initial retrospective cohort of 788  patients13.
HPV prevalence and factors associated with HPV positivity in OPC. Table  1 shows the demo-
graphic and clinical characteristics of the 864 patients included in the analysis, as well as the crude and adjusted 
prevalences and odds ratios for double positivity for HPV-DNA/p16INK4a. Patients had a mean age at diagnosis 
of 60 years; they were mostly male (88.9%), heavy smokers (74.4%) and heavy drinkers (49.7%). The most com-
mon anatomical subsite was the tonsil (40.5%). Most tumours (63.3%) were squamous cell carcinoma (SCC) 
with conventional keratinizing morphological features and the most common stage was IVa according to the 7th 
TNM edition (45.6%). The adjusted prevalence of HPV-related patients was 9.7%.
After adjustment for confounders, HPV-related patients were more likely to be younger than 60 years, non-
smokers and non-drinkers, to have tonsillar carcinoma, and to be diagnosed in most recent periods or with stages 
III–IVa (Table 1). The equivalent results for  p16INK4a positivity alone are presented in supplementary Table 1.
HPV prevalence and factors associated with HPV positivity by anatomical subsite. The associ-
ations of HPV-positivity with the demographic and clinical characteristics of OPC patients were also examined, 
stratified by three major anatomical subsites (tonsil, base of tongue and others, Table 2). None of the associa-
tions observed in the multivariable analysis for OPC including all sites were observed for subsites other than the 
tonsil and base of tongue. Crude and adjusted HPV prevalences stratified by the three major anatomical sites 
are presented for HPV-DNA/p16INK4a double-positivity and  p16INK4a-positivity alone in supplementary Tables 3 
and 4, respectively.
Some differences were observed when only  p16INK4a-positivity was analysed, for all OPC sites and by subsite 
(supplementary Tables 1 and 2, respectively). Of note, calendar period and age did not show a clear trend in the 
multivariable analysis for all OPC sites and for tonsil.
HPV type distribution. Most HPV-DNA positive cases were HPV16 (82.2%), followed by HPV33 (5.9%) 
and HPV35 (4.0%), (Table 3). When we focused on patients that were double positive for HPV-DNA/p16INK4a, 
the percentage of HPV16 and HPV35 positive patients increased to 88.5% and 5.1%, respectively, but decreased 
for other genotypes (Table 3). The same was observed specifically for all anatomical subsites, and the highest 
proportion of HPV16 was found in sites other than tonsil and base of tongue.
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Characteristics OPC samples (n = 864) No. (%)a
HPV-DNA detection AND  p16INK4a high expression (n = 78)
Crude prevalence No. (%)b Adjusted  prevalencec (%) Crude OR [95% CI] Adjusted  ORc [95% CI]
Age at diagnosis (years)
 ≤ 60 456 (52.9) 46 (10.1) 13.1 1.4 [0.8–2.2] 3.0 [1.6–5.7]
 > 60 406 (47.1) 31 (7.6) 6.8 Ref Ref
Mean age at diagnosis (SD) 60.3 (10.7) 58.7 (13.4)
Age range 28–93 28–93
Gender
Male 766 (88.9) 57 (7.4) 9.3 Ref Ref
Female 96 (11.1) 21 (21.9) 11.1 3.4 [2.0–5.9] 1.3 [0.6–2.8]
Centerd
H Mar 100 (11.6) 6 (6.0) Ref
H ICO-Bellvitge 241 (27.9) 18 (7.5) 1.2 [0.5–2.9]
H Parc Taulí 84 (9.7) 5 (6.0) 1.0 [0.3–2.9]
H Sant Pau 439 (50.8) 49 (11.2) 1.9 [0.8–4.2]
Period of diagnosis
1991–1996 140 (16.2) 7 (5.0) 7.7 Ref Ref
1997–2001 97 (11.2) 2 (2.1) 2.7 0.4 [0.1–1.7] 0.2 [0.1–1.1]
2002–2006 221 (25.6) 16 (7.2) 8.6 1.4 [0.6–3.2] 1.2 [0.4–3.1]
2007–2011 257 (29.7) 21 (8.2) 8.4 1.6 [0.7–3.6] 1.1 [0.4–2.9]
2012–2016 149 (17.2) 32 (21.5) 18.3 4.9 [2.2–10.7] 4.3 [1.6–11.4]
Tobacco use
Non-smoker 90 (11.2) 36 (40.0) 23.4 15.8 [8.2–28.3] 9.4 [4.3–20.7]
< 20 cigarettes/day 116 (14.4) 19 (16.4) 11.1 4.6 [2.5–8.7] 2.7 [1.3–5.7]
≥ 20 cigarettes/day 598 (74.4) 23 (3.8) 5.3 Ref Ref
Alcohol consumption
Non-drinker 161 (20.0) 46 (28.6) 14.7 27.0[11.4–64.2] 10.2 [3.8–27.5]
 < 100 g/day 245 (30.4) 27 (11.0) 12.4 8.3 [3.4–20.2] 7.8 [3.0–20.1]
 ≥ 100 g/day 401 (49.7) 5 (1.2) 2.6 Ref Ref
Subsite
Tonsil 350 (40.5) 53 (15.1) 14.1 5.6 [2.8–11.1] 5.2 [2.4–11.5]
BOT 189 (21.9) 16 (8.5) 7.5 2.8 [1.3–6.3] 1.9 [0.8–4.9]
Tonsil & BOT 19 (2.2) 0 (0.0) 2.2 0.4 [0.0–7.6] 0.4 [0.0–8.8]
Otherse 306 (35.4) 9 (2.9) 4.7 Ref Ref
Stage (7th edition TNM)
I&II 183 (21.3) 6 (3.3) 4.4 Ref Ref
III 184 (21.4) 19 (10.3) 12.2 3.1 [1.3–7.3] 4.7 [1.7–12.6]
IVa 393 (45.6) 49 (12.5) 11.6 3.8 [1.7–8.5] 4.3 [1.7–10.6]
IVb 82 (9.5) 4 (4.9) 6.1 1.4 [0.4–4.5] 1.6 [0.4–6.0]
IVc 19 (2.2) 0 (0.0) 2.5 0.3 [0.0–6.8] 0.5 [0.0–13.6]
Histologyd
SCC Conventional keratinizing 547 (63.3) 20 (3.7) Ref
SCC Conventional non-kerati-
nizing 234 (27.1) 28 (12.0) 3.4 [1.9–6.0]
SCC Basaloid, papillary, exophitic 73 (8.4) 29 (39.7) 16.2 [8.6–30.5]
SCC Sarcomatoid 3 (0.3) 0 (0.0) 0.7 [0.0–28.3]
Non-SCCf 7 (0.8) 1 (14.3) 3.0 [0.4–24.3]
Total 864 78 (9.0) 9.7
Table 1.  Association of demographic and clinical characteristics of OPC patients and HPV double positivity 
for HPV-DNA/p16INK4a. OPC Oropharyngeal carcinoma, SD Standard deviation, H Hospital, SCC Squamous 
cell carcinoma, BOT base of tongue, CI credibility interval. a Column percentage. bRow percentage. cAdjusted 
by age at diagnosis, gender, period of diagnosis, subsite, tobacco and alcohol consumption and stage. 
dNot considered in the multivariable model. eOthers include: Soft palate-C05.1, Uvula-C05.2, Vallecula, 
Glossoepiglottic fold, lateral and posterior wall of the oropharynx, overlapping lesion of the oropharynx and 
oropharynx unspecified-C10, Waldeyer ring-C14.2. fNon SCC include: 4 undifferentiated (1 of them HPV 
double positive) and three neuroendocrine carcinomas. In bold those estimates showing a clear association 
with HPV-DNA/p16INK4a positivity (i.e. credibility intervals do not contain 1.0).
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Characteristics
HPV-DNA detection AND high  p16INK4a expression
Tonsil samples 





Adjusted  ORa 
[95% CI]
BOT samples 














Adjusted  ORa 
[95% CI]
Age at diagnosis (years)
 ≤ 60 30/182 (16.5) 1.2 [0.7–2.2] 3.5 [1.5–7.8] 12/100 (12.0) 3.4 [1.1–11.2] 3.9 [0.9–17.4] 4/163 (2.5) 0.7 [0.2–2.5] 0.9 [0.2–3.6]
 > 60 23/168 (13.7) Ref Ref 3/88 (3.4) Ref Ref 5/142 (3.5) Ref Ref
Gender
Male 40/302 (13.2) Ref Ref 10/168 (6.0) Ref Ref 7/279 (2.5) Ref Ref
Female 13/47 (27.7) 2.4 [1.2–4.9] 1.2 [0.5–3.0] 6/21 (28.6) 5.6 [1.8–16.9] 1.7 [0.3–8.2] 2/26 (7.7) 2.7 [0.6–12.8] 1.1 [0.2–6.1]
Centerc
H Mar 5/49 (10.2) Ref 1/22 (4.5) Ref 0/27 (0.0) Ref
H ICO-Bellvitge 15/108 (13.9) 1.3 [0.5–3.5] 3/70 (4.3) 0.9 [0.2–5.5] 0/51 (0.0) 0.5 [0.0–20.1]
H Parc Taulí 5/39 (12.8) 1.2 [0.4–3.9] 0/13 (0.0) 0.3 [0.0–7.9] 0/27 (0.0) 0.7 [0.0–29.9]
H Sant Pau 28/154 (18.2) 1.8 [0.7–4.5] 12/84 (14.3) 3.3 [0.6–16.7] 9/201 (4.5) 9.4 [0.4–204.9]
Period of diagnosis
1991–1996 4/32 (12.5) Ref Ref 1/31 (3.2) Ref Ref 2/76 (2.6) Ref Ref
1997–2001 2/46 (4.3) 0.4 [0.1–1.6] 0.3 [0.0–1.4] 0/18 (0.0) 0.3 [0.0–6.4] 0.3 [0.1–8.3] 0/31 (0.0) 0.3 [0.0–6.0] 0.3 [0.0–6.7]
2002–2006 10/97 (10.3) 0.8 [0.3–2.41] 0.9 [0.2–3.4] 4/59 (6.8) 1.5 [0.3–7.7] 1.8 [0.3–10.7] 2/57 (3.5) 1.3 [0.2–6.9] 1.6 [0.3–9.6]
2007–2011 15/109 (13.8) 1.1 [0.4–3.2] 0.8 [0.2–2.8] 3/49 (6.1) 1.4 [0.3–7.3] 2.9 [0.4–19.0] 3/92 (3.3) 1.2 [0.3–5.6] 1.0 [0.2–5.0]
2012–2016 22/66 (33.3) 3.4 [1.2–9.6] 4.1 [1.1–15.2] 8/32 (25.0) 6.9 [1.5–31.9] 10.3 [1.6–67.0] 2/50 (4.0) 1.5 [0.3–7.9] 1.4 [0.2–8.2]
Tobacco use
Non-smoker 24/46 (52.2) 14.7 [6.9–31.4] 13.3 [4.8–36.9] 8/21 (38.1) 15.5 [4.5–52.7] 4.6 [0.9–22.2] 4/22 (18.2) 9.2 [2.1–37.0] 5.7 [0.9–35.8]
 < 20 cigarettes/
day 14/54 (25.9) 4.7 [2.2–10.3] 2.6 [1.1–6.6] 4/18 (22.2) 6.9 [1.7–27.5] 3.7 [0.7–20.1] 1/40 (2.5) 1.2 [0.2–7.8] 1.2 [0.2–8.5]
 ≥ 20cigarettes/
day 15/235 (6.4) Ref Ref 4/135 (3.0) Ref Ref 4/214 (1.9) Ref Ref
Alcohol consumption
Non-drinker 31/91 (34.1) 19.7 [6.8–57.2] 10.4 [3.1–35.1] 11/31 (35.5) 26.4 [5.6–124.5] 10.0 [1.6–63.3] 4/37 (10.8) 9.6 [1.8–51.2] 4.6 [0.6–36.7]
 < 100 g/day 19/95 (20.0) 9.5 [3.2–28.2] 10.4 [3.2–34.4] 4/58 (6.9) 3.5 [0.7–18.1] 2.8 [0.5–16.3] 4/85 (4.7) 4.0 [0.8–20.6] 3.7 [0.7–19.9]
 ≥ 100 g/day 3/151 (2.0) Ref Ref 1/87 (1.1) Ref Ref 1/154 (0.6) Ref Ref
Stage (7th edition TNM)
I&II 6/89 (6.7) Ref Ref 0/17 (0.0) 0.2 [0.0–3.5] 0.5 [0.0–12.5] 0/74 (0.0) 0.2 [0.0–3.0] 0.2 [0.0–3.1]
III 13/72 (18.1) 2.7 [1.1–7.0] 5.0 [1.6–15.5] 4/38 (10.5) Ref Ref 2/72 (2.8) Ref Ref
IVa 31/152 (20.4) 3.2 [1.4–7.4] 3.4 [1.3–9.2] 12/100 (12.0) 1.4 [0.4–4.6] 1.5 [0.3–7.2] 6/130 (4.6) 1.8 [0.4–7.4] 1.8 [0.4–8.1]
IVb 3/27 (11.1) 1.5 [0.4–5.8] 1.2 [0.3–5.5] 0/28 (0.0) 0.1 [0.0–2.3] 0.2 [0.0–5.4] 1/24 (4.2) 1.5 [0.2–11.6] 2.1 [0.2–19.2]













20/36 (55.6) 15.8 [7.0–36.0] 7/16 (43.8) 19.5 [5.1–74.2] 2/19 (10.5) 6.9 [1.1–41.9]
SCC Sarcoma-
toid 0/1 (0.0) 0.8 [0.0–40.5] 0/1 (0.0) 0.8 [0.0–61.3] 0/1 (0.0) 0.9 [0.0–90.6]
Non-SCCd 0/4 (0.0) 0.5 [0.0–13.9] 1/3 (33.3) 7.8 [0.7–93.2] - -
Total 53/350 (15.1) 16/189 (8.5) 9/306 (2.9)
Table 2.  Association of demographic and clinical characteristics of OPC patients and HPV double positivity 
for HPV-DNA/p16INK4a stratified by the three major anatomical sites (tonsil / base of tongue/others). OPC 
oropharyngeal carcinoma, H hospital, SCC squamous cell carcinoma, BOT base of tongue, CI credibility 
interval. a Adjusted by age, gender, period of diagnosis, subsite, tobacco and alcohol consumption and stage. 
bOthers include: Soft palate-C05.1, Uvula-C05.2, Vallecula, Glossoepiglottic fold, laterall and posterior wall of 
the oropharynx, overlapping lesion of the oropharynx and oropharynx unspecified-C10, Waldeyer ring-C14.2. 
cNot considered in the multivariable model. dNon SCC include: 4 undifferentiated (1 of them HPV double 
positive) and three neuroendocrine carcinomas. In bold those estimates showing a clear association with HPV-
DNA/p16INK4a positivity (i.e. credibility intervals do not contain 1.0).
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Time trends for HPV positivity. In the time-trend analysis, an increasing RR for HPV positivity was 
observed when period of diagnosis was analysed as a continuous variable (30% for every 5-year period, supple-
mentary Table 5). When period of diagnosis was considered as a categorical variable, we found the increase to be 
highest (RR = 2.0, 95% CI 1.1–3.9) and with a clear increasing trend only in the last 5-year period (2012–2016, 
Fig. 1 and supplementary Table 6). Since the most recent patients came mostly from Sant Pau Hospital, a sen-
sitivity analysis including only Sant Pau patients was performed, and equivalent results were obtained when 
considering period of diagnosis as a continuous variable (RR = 1.2, 95% CI 1.0–1.4). This trend was not observed 
when period of diagnosis was considered as a categorical variable (RR = 1.8, 95% CI 0.6–5.8), probably due to 
the lower number of cases. An increasing trend for risk, of 31% and 66% for every 5-year period when period of 
diagnosis was considered as a continuous variable, was also detected specifically for tonsillar and base of tongue 
cancers, respectively (supplementary Tables 6 and 7). When period of diagnosis was considered as a categorical 
Table 3.  HPV type-specific prevalence by anatomical site according to HPV-DNA and HPV-DNA/
p16INK4a positivity. OPC oropharyngeal cancer, Others include: Soft palate-C05.1, Uvula-C05.2, Vallecula, 
Glossoepiglottic fold, laterall and posterior wall of the oropharynx, overlapping lesion of the oropharynx and 
oropharynx unspecified-C10, Waldeyer ring-C14.2.
Genotype HPV-DNA HPV-DNA/  p16INK4a
OPC all sites Prevalence N (%) Prevalence N (%)
HPV16 83 (82.2) 69 (88.5)
HPV18 2 (2.0) 1 (1.3)
HPV31 1 (1.0) 0 (0.0)
HPV33 6 (5.9) 4 (5.1)
HPV35 4 (4.0) 4 (5.1)
HPV51 1 (1.0) 0 (0.0)
HPV58 1 (1.0) 0 (0.0)
HPVX 3 (3.0) 0 (0.0)
Total 101 (100.0) 78 (100.0)
Tonsil
HPV16 49 (79.0) 45 (84.9)
HPV18 2 (3.2) 1 (1.9)
HPV31 0 (0.0) 0 (0.0)
HPV33 6 (9.7) 4 (7.6)
HPV35 3 (4.8) 3 (5.7)
HPV51 0 (0.0) 0 (0.0)
HPV58 0 (0.0) 0 (0.0)
HPVx 2 (3.2) 0 (0.0)
Total 62 (100.0) 53 (100.0)
Base of tongue
HPV16 18 (85.7) 15 (93.7)
HPV18 0 (0.0) 0 (0.0)
HPV31 1 (4.8) 0 (0.0)
HPV33 0 (0.0) 0 (0.0)
HPV35 1 (4.8) 1 (6.3)
HPV51 0 (0.0) 0 (0.0)
HPV58 1 (4.8) 0 (0.0)
HPVx 0 (0.0) 0 (0.0)
Total 21 (100.0) 16 (100.0)
Others
HPV16 16 (88.9) 9 (100.0)
HPV18 0 (0.0) 0 (0.0)
HPV31 0 (0.0) 0 (0.0)
HPV33 0 (0.0) 0 (0.0)
HPV35 0 (0.0) 0 (0.0)
HPV51 1 (5.6) 0 (0.0)
HPV58 0 (0.0) 0 (0.0)
HPVx 1 (5.6) 0 (0.0)
Total 18 (100.0) 9 (100.0)
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Figure 1.  Time trends of relative risk for HPV positivity in OPC. CI credibility interval; OPC oropharyngeal 
cancer. Time trends of relative risk for HPV positivity in OPC for each five years period with respect to reference 
one: 1991–1996. Trends models adjusted by age at diagnosis, gender, period of diagnosis, subsite, stage and 
tobacco and alcohol consumption. Y axis is represented in logarithmic scale.
Figure 2.  Time trends of relative risk for HPV positivity in OPC by anatomical subsite and gender. CI 
credibility interval, BOT base of tongue. Time trends of relative risk for HPV positivity in OPC for each five 
years period with respect to reference one: 1991–1996. Trends models adjusted by age at diagnosis, gender, 
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variable, the increase was found only for base of tongue patients in the last 5-year period (Fig. 2). Increasing 
trends in HPV prevalence seemed to be higher in men than in women (Fig. 2 and supplementary Tables 8 and 9).
Discussion
To our knowledge, this study is the largest and most comprehensive assessment of the epidemiological landscape 
of HPV-related and non-related OPC in southern Europe. We had previously hypothesized that differences on 
the epidemiology of HPV-related OPC between regions may reflect distinct trends in temporal, geographical, 
and sociodemographic shifts in population exposure to both tobacco smoking and oral HPV infection, leading 
to a rapidly evolving epidemiology of HPV-related OPC 10.
Observed HPV prevalences were about 10%, as defined by the percentage of cases that were double positive 
for HPV-DNA/p16INK4a. A recent Italian study also evaluated the role of HPV in patients with newly diagnosed 
OPC during the period 2000–2018, reporting a prevalence of HPV-driven OPC of 32.3% and a higher prevalence 
in the most recent  years14. The lower prevalence observed in our cohort could be explained by the higher number 
of patients and the inclusion of patients diagnosed at earlier calendar periods than in the Italian study. Moreover, 
epidemiological differences between the two populations could also exist and account for such differences. As 
 expected10, the highest HPV prevalences were observed in tonsillar cancers, with 14% of patients estimated to 
be HPV-related compared with 8% of base of tongue and 5% of other cancer subsites. Also, in accordance with 
the  literature8,9, higher HPV prevalences were observed in more advanced stages based on 7th TNM definition 
(III and IVa) compared with early stages (I and II).
Our results indicate that HPV prevalences in OPC have started to increase sharply in the most recent years 
in our setting. However, our results reporting HPV prevalence estimates are based on primary OPC tumours 
from four hospital-based registries and do not necessarily imply an increasing incidence of HPV-associated OPC 
in our region. Nevertheless, a previous study estimating the incidence trends of OPC in Spain by using data 
from population-based registries predicted statistically significant increasing trends for OPC over the period 
2003–201721. These results, together with our own, support the hypothesis that these increasing trends for OPC 
are caused by HPV infection. Of note, age-standardized incidence rates for OPC were estimated in 2018 at 1.4 
in Spain and 1.3 in southern Europe,  respectively22.
If this hypothesis is correct, HPV-related OPC has started to increase in our setting about 20 years later than 
in other countries such as the  US3. This two-decade gap is in agreement with the calendar period differences 
between smoking drops in the US and Spain (supplementary Fig. 2).
However, it is still unclear whether tobacco and/or alcohol use can act as co-factors and/or effect modifiers in 
the risk of developing HPV-related  OPC23. Therefore, we cannot rule out the possibility that smoking is associated 
with an increased risk of HPV-positive OPC, as observed in previous studies in the  US24.
The increased trends in HPV prevalence were not observed for cancers located at sites other than the tonsil 
and base of tongue and were more marked in the latter, although the credibility intervals were wider due to the 
lower number of base of tongue cancers.
After adjustment for confounders, HPV prevalences were found to be higher in younger patients, as observed 
in other high-burden regions. Of note, most recent publications from the US indicate that a rising proportion 
of older OPC patients have HPV-positive  tumours25,26. HPV prevalences were substantially higher in women 
than in men, in contrast with what is observed, for instance, in the  US3. This was already observed for Europe 
in an international cross-sectional study conducted by our  group10. However, after adjustment for confounders, 
those gender differences disappeared. A recent Italian study that did not adjust for confounders also observed 
higher HPV prevalences in women than in men in the univariate  analyses14. Our results after adjustment for 
confounders were supported by the finding of a lower number of ever-smokers among female (62/94, 66.0%) 
than male (650/709, 91.7%) patients. A systematic review on geographical differences in the proportion of HPV 
prevalence in OPC between men and women revealed that those differences were mainly a consequence of the 
vast international variation in male smoking  habits27. Notwithstanding, a population-based study describing 
time trends of cancer incidence and mortality in Catalonia during the period 1993–2007 detected a rising trend 
in oral cavity and pharyngeal cancers among women but not among men, presumably explained by a higher and 
earlier rate of smoking cessation among men than among  women28. In addition to smoking differences between 
men and women, HPV transmission appears higher from women to men among heterosexual  partners29 and 
differences in sexual behaviours between geographical regions have not been analysed at this level of detail. 
Intriguingly, although this study was not powered to precisely evaluate this issue due to the low number of female 
patients, increasing trends in HPV prevalence were suggested to be higher in women than in men (Fig. 2 and 
Supplementary Tables 8 and 9).
The gender and calendar differences in OPC HPV prevalence between high-burden regions and our setting 
could also be partially explained by differences in sexual behaviour, which is a clear risk factor for oral HPV 
acquisition and HPV-related OPC. Indeed, sexual behaviour greatly varies across regions with proportions of ever 
having oral sex in the US being higher than 65% compared with less than 20% in countries in southern Europe 
such as  Spain30. Nevertheless, the CLEOPATRE study, which aimed to estimate the prevalence of cervical HPV 
infection in Spanish women attending cervical cancer screening, found a higher number of sexual partners and 
earlier ages for sexual debut in younger (18–25 years) versus the oldest women (56–65 years)31. The CLEOPA-
TRE results could thus also partially account for the recent increasing trends in HPV prevalence observed in the 
present study if it is assumed that changes in oral sex practices have also taken place.
Different trends in tonsillectomy rates could also have contributed to the observed geographical heterogene-
ity. A previous study from Denmark reported a decrease in tonsillectomy rates concomitant to a simultaneous 
increase in the risk of  OPC32. However, other studies did not find that the observed significant increases in OPC 
were related to declines in  tonsillectomies33,34 reinforcing increased oral HPV exposure as the likely cause.
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The differences in the role of HPV in OPC between anatomical subsites observed in our study are consistent 
with the results of a recent systematic  review35 concluding that HPV prevalence differs markedly between OPC 
subsites and that its role in sites “other” than tonsil or base of tongue is uncertain and needs further evaluation.
A total of 30 out of 108 (27.7%)  p16INK4a positive cases were HPV-DNA negative, representing 3.5% of the 
total sample, despite definition of  p16INK4a positivity as staining above > 70%. This percentage is higher than the 
10%-20% observed in most studies irrespective of the method of HPV-specific testing  applied36, although it is 
lower than the 47% reported in an Italian study that considered a case to be  p16INK4a positive if strong nuclear 
and cytoplasmic staining was present in > 50% of the tumour  cells37. Classification and potential management 
of  p16INK4a-positive—HPV-negative cases is still  controversial38,39 although  we13 and  others37,39 have shown 
that these cases display similar survival to  p16INK4a-negative cases. Moreover, molecular characterization of 
 p16INK4a-positive—HPV-negative OPC cases has shown a similar genetic profile to HPV-negative  tumours40. 
In this regard, we have observed epidemiological differences between OPC cases that were double positive 
for HPV-DNA/p16INK4a and cases that were  p16INK4a-positive only, such as the loss of association with age and 
calendar period. Age discrepancies could be explained by a higher accumulation of mutations with age in the 
case of  p16INK4a—positive—HPV-negative patients. A powered study aiming to perform an in-depth compari-
son between  p16INK4a-positive—HPV-positive cases and  p16INK4a-positive—HPV-negative cases is warranted to 
elucidate these questions.
Our study has several limitations. Selection of patients was not population-based and thus our results cannot 
be extrapolated to the general population. Moreover, the modest sample size does not allow firm conclusions 
to be drawn regarding associations with HPV positivity by subsite or gender, for instance. However, accord-
ing to preliminary estimates of the OPC incidence in Catalonia using data from population-based  registries41, 
about one third of OPC cases diagnosed each year in Catalonia are seen at the four hospitals of the study, and 
our sample represents approximately 16% of all incident OPC cases in the region. The retrospective nature of 
our cohort may have hampered thorough characterization of patients according to risk factors such as tobacco 
or alcohol use, since this kind of information could only be partially obtained from medical records. The more 
recent patients were only available for inclusion in the study for Sant Pau Hospital. However, when we addressed 
this limitation by performing a sensitivity analysis only considering Sant Pau patients, we obtained equivalent 
results. In addition, paraffin blocks were not available at diagnosis for a substantial number of patients, notably 
those with base of tongue carcinoma, a location particularly difficult to biopsy, as well as for patients from older 
periods. Of note, a fraction of these patients (3% from Bellvitge Hospital) had fine needle aspiration samples. 
However, these were not included according to our exclusion criteria. Our classification of subsites other than 
tonsil or base of tongue comprised many different locations, including oropharynx unspecified or overlapping 
lesions that could also include tonsil and base of tongue.
Our findings indicate that HPV prevalence in OPC has started to sharply increase in the most recent years 
in our setting. These results, together with previous estimates of increasing trends of OPC in Spain, suggest that 
HPV-related OPC has started to increase as occurred two decades ago in areas where most OPC cases are cur-
rently HPV-related. However, there are some differences between the epidemiology of the disease in our setting 
and other high-burden regions and we do not yet know whether they may change in the near future to approach 
the epidemiology of HPV-related OPC in high-burden regions.
Importantly, our results strongly suggest that current estimates of HPV prevalence in southern Europe (prob-
ably other regions beyond high-burden areas) are outdated and warrant updated studies in selected populations. 
Continuing surveillance of sexual behaviours, alongside HPV vaccination status, is warranted to predict future 
HPV-related OPC burden.
Received: 26 February 2020; Accepted: 21 July 2020
References
 1. IARC. IARC Monographs on the evaluation of carcinogenic risks to humans. Monograph 89, 223–276 (2007).
 2. De Martel, C., Plummer, M., Vignat, J. & Franceschi, S. Worldwide burden of cancer attributable to HPV by site country and HPV 
type. Int. J. Cancer 141(4), 664–670 (2017).
 3. Chaturvedi, A. K. et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J. Clin. Oncol. 29, 
4294–4301 (2011).
 4. Nasman, A. et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: An epidemic of 
viral-induced carcinoma?. Int. J. Cancer 125, 362–366 (2009).
 5. Hannisdal, K., Schjølberg, A., De Angelis, P. M., Boysen, M. & Clausen, O. P. Human papillomavirus (HPV)-positive tonsillar 
carcinomas are frequent and have a favourable prognosis in males in Norway. Acta Otolaryngol. 130, 293–299 (2010).
 6. Garnaes, E. et al. A high and increasing HPV prevalence in tonsillar cancers in Eastern Denmark, 2000–2010: The largest registry-
based study to date. Int. J. Cancer 136(9), 2196–2203 (2015).
 7. Rietbergen, M. M. et al. Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Nether-
lands as assessed by a validated test algorithm. Int. J. Cancer 132, 1565–1571 (2013).
 8. Gillison, M. L., Chaturvedi, A. K., Anderson, W. F. & Fakhry, C. Epidemiology of human papillomavirus-positive head and neck 
squamous cell carcinoma. J. Clin. Oncol. 33(29), 3235–3242 (2015).
 9. Taberna, M. et al. Human papillomavirus-related oropharyngeal cancer. . Ann. Oncol. 00, 1–13 (2017).
 10. Castellsagué, X. et al. HPV Involvement in head and neck cancers: Comprehensive assessment of biomarkers in 3680 patients. J. 
Natl. Cancer Inst. 108(6), djv03 (2016).
 11. Rodrigo, J. P. et al. Time trends in the prevalence of HPV in oropharyngeal squamous cell carcinomas in northern Spain (1990–
2009). Int. J. Cancer 134(2), 487–492 (2014).




Scientific RepoRtS |        (2020) 10:13219  | https://doi.org/10.1038/s41598-020-70118-7
www.nature.com/scientificreports/
 13. Mena, M. et al. Double positivity for HPV-DNA/p16INK4a is the biomarker with strongest diagnostic accuracy and prognostic value 
for human papillomavirus related oropharyngeal cancer patients. Oral. Oncol. 78, 137–144 (2018).
 14. Del Mistro, A. et al. Age-independent increasing prevalence of human papillomavirus-driven oropharyngeal carcinomas in North-
East Italy. Sci. Rep. 10(1), 9320 (2020).
 15. Westra, W. H. Detection of human papillomavirus (HPV) in clinical samples: Evolving methods and strategies for the accurate 
determination of HPV status of head and neck carcinomas. Oral. Oncol. 50(9), 771–779 (2014).
 16. Leeper, T. J. Prediction: Tidy, Type-Safe ’prediction()’ Methods. R package version 0.2.0 (2017).
 17. Alemany, L. et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int. J. Cancer 
136(1), 98–107 (2015).
 18. Clèries, R. et al. Monitoring the decreasing trend of testicular cancer mortality in Spain during 2005–2019 through a Bayesian 
approach. Cancer Epidemiol. 34(3), 244–256 (2010).
 19. Gelman, A., & Su, Y. Arm: Data Analysis Using Regression and Multilevel/Hierarchical Models. R package version 1.9–3 (2016).
 20. Botta, L. et al. Angelis R, et al on behalf of the RARECAREnet Working group. Bayesian estimates of the incidence of rare cancers 
in Europe. Cancer Epidemiol. 54, 95–100 (2018).
 21. de Souza, D. L., Pérez, M. M. & Curado, M. P. Predicted incidence of oral cavity, oropharyngeal, laryngeal, and hypopharyngeal 
cancer in Spain and implications for cancer control. Cancer Epidemiol. 35(6), 510–514 (2011).
 22. Ferlay, J. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 
144(8), 1941–1953 (2019).
 23. Gillison, M. L. et al. Human papillomavirus and diseases of the upper airway: Head and neck cancer and respiratory papillomatosis. 
Vaccine 30(Suppl 5), F34–F54 (2012).
 24. Chaturvedi, A. K., D’Souza, G., Gillison, M. L. & Katki, H. A. Burden of HPV-positive oropharynx cancers among ever and never 
smokers in the U.S. Population. Oral Oncol 60, 61–7 (2016).
 25. Rettig, E. M. et al. Oropharyngeal cancer is no longer a disease of younger patients and the prognostic advantage of human papil-
lomavirus is attenuated among older patients: Analysis of the national cancer database. Oral. Oncol. 83, 147–153 (2018).
 26. Windon, M. J. et al. Increasing prevalence of human papillomavirus-positive oropharyngeal cancers among older adults. Cancer 
124(14), 2993–2999 (2018).
 27. Combes, J. D., Chen, A. A. & Franceschi, S. Prevalence of human papillomavirus in cancer of the oropharynx by gender. Cancer 
Epidemiol. Biomark. Prev. 23(12), 2954–2958 (2014).
 28. Cleries, R. et al. Time trends of cancer incidence and mortality in Catalonia during 1993–2007. Clin. Transl. Oncol. 16(1), 18–28 
(2014).
 29. Giuliano, A. R. et al. EUROGIN 2014 roadmap: Differences in human papillomavirus infection natural history, transmission and 
human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int. J. Cancer 136(12), 2752–2760 (2015).
 30. Heck, J. E. et al. Sexual behaviours and the risk of head and neck cancers: A pooled analysis in the International Head and Neck 
Cancer Epidemiology (INHANCE) consortium. Int. J. Epidemiol. 39(1), 166–181 (2010).
 31. Castellsagué, X. et al. Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: The CLEOPA-
TRE study. J. Med. Virol. 84(6), 947–956 (2012).
 32. Fakhry, C., Andersen, K. K., Christensen, J., Agrawal, N. & Eisele, D. W. The impact of tonsillectomy upon the risk of oropharyngeal 
carcinoma diagnosis and prognosis in the danish cancer registry. Cancer Prev. Res. (Phila.) 8(7), 583–589 (2015).
 33. Chaturvedi, A. et al. Tonsillectomy and incidence of oropharyngeal cancers. Cancer Epidemiol. Biomark. Prev. 25(6), 944–950 
(2016).
 34. Schache, A. G. et al. HPV-related oropharynx cancer in the United Kingdom: An evolution in the understanding of disease etiol-
ogy. Cancer Res. 76(22), 6598–6606 (2016).
 35. Haeggblom, L., Ramqvist, T., Tommasino, M., Dalianis, T. & Näsman, A. Time to change perspectives on HPV in oropharyngeal 
cancer. A systematic review of HPV prevalence per oropharyngeal sub-site the last 3 years. Papillomavirus Res 4, 1–11 (2017).
 36. Grønhøj Larsen, C. et al. Correlation between human papillomavirus and p16 overexpression in oropharyngeal tumours: A sys-
tematic review. Br. J. Cancer 110(6), 1587–1594 (2014).
 37. Perrone, F. et al. Isolating p16 positive/HPV negative oropharyngeal cancer: An effort worth making. Am. J. Surg. Pathol. 2011(35), 
774–777 (2011).
 38. Jordan, R. C. et al. Validation of methods for OPC HPV status determination in US cooperative group trials. Am. J. Surg. Pathol. 
36(7), 945–954 (2012).
 39. Coordes, A. et al. Meta-analysis of survival in patients with HNSCC discriminates risk depending on combined HPV and p16 
status. Eur. Arch. Otorhinolaryngol. 273(8), 2157–2169 (2016).
 40. Rietbergen, M. M. et al. Molecular characterization of p16-immunopositive but HPV DNA-negative oropharyngeal carcinomas. 
Int. J. Cancer 134(10), 2366–2372 (2014).
 41. Galceran, J., Ameijide, A., Alemany, L., Carulla, M., Marcos, R., Vilardell, L., et al. Incidence and mortality of neoplasias related to 
Human papillomavirus in Catalonia. In XXXV Scientific Meeting of the Spanish Society of Epidemiology (SEE), Oral Presentation, 
(2017).
Acknowledgements
We thank CERCA Program / Generalitat de Catalunya for institutional support and all members of the study 
group: Catalan Institute of Oncology/Hospital Universitari de Bellvitge: Laia Alemany, Xavier Bosch, Vanesa 
Camon, Omar Clavero, Ana Esteban, Yolanda Florencia, Montserrat Gomà, Alicia Lozano, Manel Maños, Anto-
nio Marí, Marisa Mena, Ricard Mesía, Julio Nogués, Oriol Bermejo, Ramon Clèries, Jon Frias-Gomez, Miquel 
Ángel Pavón, Beatriz Quirós, Silvia de Sanjosé, Miren Taberna, Montserrat Torres, Sara Tous, Griselda Venturas, 
Marleny Vergara; Hospital General de l’Hospitalet: María Alejo; Hospital de la Santa Creu i Sant Pau: Jacinto 
García, Xavier León, Montserrat Lopez, Miquel Quer; Hospital del Mar: Marta Guix, Rafael Hijano, Belén Llo-
veras; Hospital Universitari Parc Taulí: Antón Aguilà, María Rosa Bella, Carmen Blazquez, Teresa Bonfill). This 
work was supported by grants from the Instituto de Salud Carlos III-ISCIII (Spanish Government) co-funded by 
FEDER funds / European Regional Development Fund (ERDF)—a way to build Europe (References: PI1102096, 
PI1401918, PI1500500, PI1501205, RD12/0,036/0,056, CIBERESP CB06/02/0,073 CIBERONC CB16/12/0,040), 
Agència de Gestió d’Ajuts Universitaris i de Recerca (2017SGR1085), Department of Health of the Generalitat 
de Catalunya (PERIS-2016–2020 SLT002/16/00,404 and SLT006/17/76), Rio Hortega-SEOM (ISCIII-Spanish 
Society of Medical Oncology) (personal grant to MT) and from Sanofi Pasteur MSD and Merck & Co, Inc., who 
had no role in the data collection, analysis or interpretation of the results.
11
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:13219  | https://doi.org/10.1038/s41598-020-70118-7
www.nature.com/scientificreports/
Author contributions
MM, LA, MT, RC and ST conceptualized the study. MM, LA, MT, RC, ST and JFG designed the study. MM, MT, 
XL, JG, RM, OB, TB, AA, MG, RH, AB collected the data. BQ, JFG, ST, MM, MT and LA assured the quality 
control of data and algorithms. OC, MTo, BLL, MA, MAP, MM, BQ, ST, MT and LA analysed and interpreted 
the data. JFG, SM, ST and RC did the statistical analyses. MM and JFG prepared the manuscript. MM edited the 
manuscript. All authors reviewed and approved the final version.
competing interests 
RM has received personal fees and non-financial support from Merck, and personal fees from Astra Zeneca and 
MSD. MT has received scientific advisory board fees, speaker’s fees, travel grants or non-financial support from 
Merck, Astra Zeneca, Nanobiotics, MSD and Bristol Meyers. Cancer Epidemiology Research Program (LA, MM, 
JF, SM, ST, BQ, OC, MT, MTo, MP) has received sponsorship for grants from Merck and co, Roche, Reig-jofre, 
IDT, Seegene, Hologic and GSK. The rest of authors have declared no conflicts of interest.
Additional information
Supplementary information  is available for this paper at https ://doi.org/10.1038/s4159 8-020-70118 -7.
Correspondence and requests for materials should be addressed to M.M. or L.A.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this license, visit http://creat iveco mmons .org/licen ses/by/4.0/.
© The Author(s) 2020
